Ferroptosis-centered Disease Response Information
General Information of the Disease (ID: DIS00048)
| Name |
Adrenocortical carcinoma
|
||||
|---|---|---|---|---|---|
| ICD |
ICD-11: 2D11
|
||||
Full List of Target(s) of This Ferroptosis-centered Disease
Unspecific Target
| In total 2 item(s) under this target | ||||
| Experiment 1 Reporting the Ferroptosis-centered Disease Response by This Target | [1] | |||
| Responsed Disease | Adrenocortical carcinoma [ICD-11: 2D11] | |||
| Responsed Drug | Romidepsin | Investigative | ||
| Responsed Regulator | Histone deacetylase 1 (HDAC1) | Suppressor | ||
| Pathway Response | Cell adhesion molecules | hsa04514 | ||
| Ferroptosis | hsa04216 | |||
| Cell Process | Cell ferroptosis | |||
| Cell proliferation | ||||
| In Vitro Model | SW13 cells | Adrenal cortex carcinoma | Homo sapiens | CVCL_0542 |
| Response regulation | HDAC inhibitor Romidepsin converted SW13+ cells also had reduced mRNA expression of the mitochondrial ROS detoxifier superoxide dismutase 2 (SOD2), and the tumor suppressor p53. HDAC inhibitor treatment synergistically increased adrenocortical carcinoma cell death following induction of ferroptosis. | |||
| Experiment 2 Reporting the Ferroptosis-centered Disease Response by This Target | [1] | |||
| Responsed Disease | Adrenocortical carcinoma [ICD-11: 2D11] | |||
| Responsed Drug | Romidepsin | Investigative | ||
| Responsed Regulator | Cellular tumor antigen p53 (TP53) | Driver | ||
| Pathway Response | Cell adhesion molecules | hsa04514 | ||
| Ferroptosis | hsa04216 | |||
| Cell Process | Cell ferroptosis | |||
| Cell proliferation | ||||
| In Vitro Model | SW13 cells | Adrenal cortex carcinoma | Homo sapiens | CVCL_0542 |
| Response regulation | HDAC inhibitor Romidepsin converted SW13+ cells also had reduced mRNA expression of the mitochondrial ROS detoxifier superoxide dismutase 2 (SOD2), and the tumor suppressor p53. HDAC inhibitor treatment synergistically increased adrenocortical carcinoma cell death following induction of ferroptosis. | |||
